IMU 2.94% 17.5¢ imugene limited

Ann: Final Highest Dose in Phase 1 Clinical Trial of PD-VAXX, page-3

  1. 1,239 Posts.
    lightbulb Created with Sketch. 65
    After 6 weeks (day 43) treatment with PD1-Vaxx, one patient’s tumor was non-measurable indicating a complete response (CR), with three patients showing stabilization of disease (SD) and a single patient progressing (PD). The status of two patients from cohort 1 (1 x SD, 1 x CR) were unchanged at day 85.

    These are encouraging results in patients who have progressed after previous treatment with checkpoint inhibitors including Keytruda®, Opdivo® or Tecentriq®. Further results and scans are scheduled over the coming weeks. The clinical results indicate that PD1-Vaxx is showing early signs of an immune responses in patients, with antibodies to the target biomarker PD1 evident in validated assays.

    Imugene MD & CEO Leslie Chong said “Phase 1 trials are generally designed to look for safety, tolerability and early response signals to determine the optimal dose for further development. I am encouraged that we are seeing positive signals at such an early stage of our PD1-Vaxx Phase I trial”.
    Last edited by Slykes: 07/04/21
watchlist Created with Sketch. Add IMU (ASX) to my watchlist
(20min delay)
Mkt cap ! $833.9M
Open High Low Value Volume
17.5¢ 18.0¢ 17.0¢ $1.227M 6.996M

Buyers (Bids)

No. Vol. Price($)
12 1372786 17.5¢

Sellers (Offers)

Price($) Vol. No.
18.0¢ 2610021 29
View Market Depth
Last trade - 16.10pm 15/04/2021 (20 minute delay) ?
0.005 ( 3.93 %)
Open High Low Volume
17.5¢ 18.0¢ 17.0¢ 4691989
Last updated 15.59pm 15/04/2021 (live) ?
IMU (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.